Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14982686 | 0.99 | NAAA (0.37) | NAAAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL15275208 | 0.87 | NAAA (0.48) | NAAAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL9976864 | 0.84 | NAAA (0.41) | NAAAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL9976828 | 0.83 | NAAA (0.39) | NAAAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL14870721 | 0.81 | ALOX15 (0.30) | — | |
| SCHEMBL15850750 | 0.81 | APP (0.35) | NAAAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL9976874 | 0.80 | CYP11B1 (0.38) | — | |
| SCHEMBL15275209 | 0.78 | NAAA (0.42) | NAAAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL15275187 | 0.78 | NAAA (0.41) | NAAAKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL9976821 | 0.77 | L3MBTL1 (0.34) | KMT2AMEN1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680296-B2 | Leaving substituent-containing compound, products produced using the same, and methods for producing the products | RICOH COMPANY, LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | RICOH COMPANY, LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120153271-A1 | LEAVING SUBSTITUENT-CONTAINING COMPOUND, ORGANIC SEMICONDUCTOR MATERIAL, ORGANIC SEMICONDUCTOR FILM CONTAINING THE MATERIAL, ORGANIC ELECTRONIC DEVICE CONTAINING THE FILM, METHOD FOR PRODUCING FILM-LIKE PRODUCT, PI-ELECTRON CONJUGATED COMPOUND AND METHOD FOR PRODUCING THE PI-ELECTRON CONJUGATED COMPOUND | F12, C1S, PYM1 | NAAA 3554/4885KMT2A 250/4885MEN1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.